It has been found that SGLT2 is functionally expressed in pancreatic cancer, and SGLT2 can activate the Hippo signaling pathway through the hnRNPK-YAP1 axis to promote the progression of pancreatic cancer (36, 37). This evidence concerns the gene YAP1 and pancreatic neoplasm.